Barclays’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $358K | Buy |
102,204
+2,113
| +2% | +$8.01K | ﹤0.01% | 3389 |
|
|
2026
Q1 | $386K | Sell |
100,091
-62,021
| -38% | -$244K | ﹤0.01% | 3336 |
|
|
2025
Q4 | $637K | Buy |
162,112
+4,003
| +3% | +$17.7K | ﹤0.01% | 3716 |
|
|
2025
Q3 | $738K | Sell |
158,109
-13,722
| -8% | -$49.6K | ﹤0.01% | 3560 |
|
|
2025
Q2 | $534K | Buy |
171,831
+60,783
| +55% | +$196K | ﹤0.01% | 3725 |
|
|
2025
Q1 | $375K | Sell |
111,048
-3,742
| -3% | -$17.5K | ﹤0.01% | 3703 |
|
|
2024
Q4 | $651K | Buy |
114,790
+10,328
| +10% | +$66.6K | ﹤0.01% | 3660 |
|
|
2024
Q3 | $611K | Buy |
104,462
+37,398
| +56% | +$272K | ﹤0.01% | 3648 |
|
|
2024
Q2 | $530K | Buy |
67,064
+8,052
| +14% | +$67.5K | ﹤0.01% | 3012 |
|
|
2024
Q1 | $549K | Sell |
59,012
-7,189
| -11% | -$60.7K | ﹤0.01% | 3529 |
|
|
2023
Q4 | $559K | Buy |
66,201
+47,892
| +262% | +$347K | ﹤0.01% | 3810 |
|
|
2023
Q3 | $142K | Buy |
18,309
+11,970
| +189% | +$109K | ﹤0.01% | 3441 |
|
|
2023
Q2 | $72.6K | Sell |
6,339
-29,097
| -82% | -$301K | ﹤0.01% | 3686 |
|
|
2023
Q1 | $273K | Buy |
35,436
+19,975
| +129% | +$159K | ﹤0.01% | 3626 |
|
|
2022
Q4 | $94.3K | Buy |
15,461
+13,563
| +715% | +$77.1K | ﹤0.01% | 4261 |
|
|
2022
Q3 | $11K | Buy |
+1,898
| New | +$12.2K | ﹤0.01% | 4281 |
|
|
2021
Q4 | – | Sell |
-3,483
| Closed | -$9K | – | 4782 |
|
|
2021
Q3 | $9K | Sell |
3,483
-3,961
| -53% | -$12.9K | ﹤0.01% | 4541 |
|
|
2021
Q2 | $31K | Sell |
7,444
-14,312
| -66% | -$64.9K | ﹤0.01% | 4360 |
|
|
2021
Q1 | $103K | Buy |
21,756
+13,222
| +155% | +$90.2K | ﹤0.01% | 3998 |
|
|
2020
Q4 | $60K | Sell |
8,534
-3,373
| -28% | -$32.4K | ﹤0.01% | 4343 |
|
|
2020
Q3 | $127K | Sell |
11,907
-5,095
| -30% | -$59.8K | ﹤0.01% | 4116 |
|
|
2020
Q2 | $215K | Buy |
17,002
+7,984
| +89% | +$92.9K | ﹤0.01% | 4013 |
|
|
2020
Q1 | $82K | Sell |
9,018
-16,517
| -65% | -$190K | ﹤0.01% | 4926 |
|
|
2019
Q4 | $356K | Sell |
25,535
-4,034
| -14% | -$58.6K | ﹤0.01% | 4570 |
|
|
2019
Q3 | $509K | Sell |
29,569
-1,828
| -6% | -$38.4K | ﹤0.01% | 4238 |
|
|
2019
Q2 | $855K | Buy |
31,397
+25,029
| +393% | +$573K | ﹤0.01% | 3848 |
|
|
2019
Q1 | $122K | Buy |
6,368
+6,167
| +3,068% | +$80.3K | ﹤0.01% | 5208 |
|
|
2018
Q4 | $2K | Sell |
201
-18,098
| -99% | -$232K | ﹤0.01% | 6741 |
|
|
2018
Q3 | $347K | Buy |
18,299
+1,430
| +8% | +$27.4K | ﹤0.01% | 4571 |
|
|
2018
Q2 | $330K | Sell |
16,869
-15,708
| -48% | -$310K | ﹤0.01% | 4308 |
|
|
2018
Q1 | $612K | Buy |
32,577
+5,415
| +20% | +$117K | ﹤0.01% | 3749 |
|
|
2017
Q4 | $451K | Buy |
27,162
+12,525
| +86% | +$215K | ﹤0.01% | 3958 |
|
|
2017
Q3 | $301K | Buy |
14,637
+4,726
| +48% | +$53.3K | ﹤0.01% | 4071 |
|
|
2017
Q2 | $89K | Buy |
9,911
+957
| +11% | +$9.63K | ﹤0.01% | 4993 |
|
|
2017
Q1 | $119K | Buy |
8,954
+7,154
| +397% | +$86.8K | ﹤0.01% | 4767 |
|
|
2016
Q4 | $23K | Buy |
1,800
+1,726
| +2,332% | +$22.2K | ﹤0.01% | 5562 |
|
|
2016
Q3 | $1K | Buy |
+74
| New | +$1K | ﹤0.01% | 6458 |
|
Other funds holding VYGR
AC
VPC
OM
Barclays's VYGR Position: Q2 2026 in Review
Barclays increased its Voyager Therapeutics (VYGR) stake by 2.1% in Q2 2026, buying an estimated $8.01K and bringing the position to 102,204 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #3389.
Barclays first reported a position in VYGR in Q3 2016 and has held it in 37 quarters since. The position peaked at $855K in Q2 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- Barclays held 102,204 shares of Voyager Therapeutics worth $358K as of Q2 2026.
- Barclays bought 2,113 Voyager Therapeutics shares in Q2 2026, an estimated $8.01K.
- Voyager Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3389 holding.
- Barclays first reported a position in Voyager Therapeutics in Q3 2016 and has held it in 37 quarters since.
- Barclays's Voyager Therapeutics position peaked at $855K in Q2 2019.
- 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.